THSNA Virtual Meeting

Announcement
Thank you for attending THSNA 2026. The virtual meeting is now closed.

Posters/Exhibits/Break > Session

Posters/Exhibits/Break

Presentations

A1. ANTICOAGULATION CLINICS
				(400) COMPARING WARFARIN DOSE DECISION MAKING BEFORE AND AFTER TRANSITION TO PATIENT SELF-MANAGEMENT Jack M. Lawrence¹, Geoffrey D. Barnes², Katelyn W. Sylvester³, Linh Chan⁴, Sara R. Vazquez⁵, Aubrey E. Jones^1,5, Spencer J. Gilbert^1,5, Daniel M. Witt^1,5. ¹University of Utah College of Pharmacy, Salt Lake City, UT, USA ²University of Michigan, Ann Arbor, MI, USA ³Brigham and Women's Hospital, Boston, MA, USA ⁴Veterans Affairs Loma Linda Healthcare System, Loma Linda, CA, USA ⁵University of Utah Health Thrombosis Service, Salt Lake City, UT, USA
A5. BLOOD COAGULATION AND FIBRINOLYTIC FACTORS
				(403) ICOAGLAB MEASURES COMPREHENSIVE COAGULATION PROFILES WITHIN MINUTES IN CARDIAC INTENSIVE CARE PATIENTS Daniel Hoare¹, Jay Saggu², Rusul Al-Ani², Kristen Warren², Aniket Joshi¹, Christoph Nabzdyk², Seemantini Nadkarni¹. ¹Wellman Center for Photomedicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA ²Division of Anesthesiology, Perioperative and Pain Medicine, Harvard Medical School, Brigham and Women’s Hospital, Boston, MA, USA
				(404) THROMBOTIC COMPLICATIONS IN SICKLE CELL ANEMIA Bhakti Singh¹, Neha Thomas¹, Atul Laddu¹, Fakiha Siddiqui², Jawed Fareed². ¹Global Thrombosis Forum, Suwanee, GA, USA ²Loyola University, Chicago, IL, USA
A6. DISORDERS OF COAGULATION OR FIBRINOLYSIS
				(405) SEX AND AGE-BASED EVALUATION OF A NEWLY FORMULATED INTRANASAL DDAVP COMPARED WITH INTRANASAL DDAVP AND SUBCUTANEOUS DDAVP IN TYPE 1 VON WILLEBRAND DISEASE Sanjay Ahuja¹, Sweta Gupta¹, Magdalena Lewandowska¹, Jennifer Maahs¹, Sonia Nasr², Amy Shapiro¹. ¹Innovative Hematology, Indiana Hemophilia & Thrombosis Center, Indianapolis, IN, USA ²GLOVAL LLC, Broomfield, CO, USA
				(406) CYTOKINE RELEASE SYNDROME AND THROMBOSIS RISK AFTER CAR-T THERAPY Courtney Crawford¹, Parmis Sahrapima¹, Joseph Shatzel^2,3, Corinne Lavasseur^2,3. ¹Department of Internal Medicine, Oregon Health and Sciences University, Portland, OR, USA, Portland, OR, USA ²Division of Hematology and Medical Oncology, Oregon Health and Sciences University, Portland, OR, USA, Portland, OR, USA ³Knight Cancer Institute, Portland, OR, USA
				(407) DEEP VEIN THROMBOSIS FOLLOWING CALF HEMATOMA IN A PEDIATRIC PATIENT WITH FACTOR VII DEFICIENCY Grace Hause, OMS-II¹, Fred Loeffler, PT, DPT, LAT, ATC, CLT², Stephanie Garrison, NP³, Nihal Bakeer, MD^3,4,5, Eman Abdelghani, MD³. ¹Marian University Wood College of Osteopathic Medicine, Indianapolis, IN, USA ²Physical Therapy, Indiana Hemophilia and Thrombosis Center, Innovative Hematology Inc., Indianapolis, IN, USA ³Innovative Hematology Inc. / Indiana Hemophilia and Thrombosis Center (IHI/IHTC), Indianapolis, IN, USA ⁴Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA ⁵Division of Hematology, Children's Hospital of Philadelphia, Philadelphia, PA, USA
				(408) MIM8 PROPHYLAXIS IN ADULTS AND ADOLESCENTS WITH HEMOPHILIA A: 52-WEEK EFFICACY AND SAFETY OUTCOMES FROM THE PHASE 3 FRONTIER2 STUDY Steven R Lentz¹, Aby Abraham², Cihan Ay³, Anthony KC Chan⁴, Victor Jiménez-Yuste⁵, Johannes Oldenburg⁶, Maria Elisa Mancuso^7,8, Johnny Mahlangu⁹, Tadashi Matsushita¹⁰, Lize van Vulpen¹¹, Renchi Yang¹², Amalie Rhode Høgh Nielsen¹³, Ilgiz Rakhmatullin¹³, Emily Waters¹⁴, Pratima Chowdary¹⁵, Maria Lage¹⁴. ¹Department of Internal Medicine, University of Iowa, Iowa City, IA, USA ²Department of Clinical Haematology, Christian Medical College, Vellore, Tamil Nadu, India ³Department of Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria ⁴McMaster Children’s Hospital, McMaster University, Hamilton, ON, Canada ⁵Hospital Universitario La Paz, Universidad Autónoma de Madrid, Madrid, Spain ⁶The Institute of Experimental Hematology and Transfusion Medicine, Universitätsklinikum Bonn, Bonn, Germany ⁷Center for Thrombosis and Hemorrhagic Diseases, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy ⁸Humanitas University, Pieve Emanuele, Milan, Italy ⁹Department of Molecular Medicine and Haematology, Faculty of Health Science, University of the Witwatersrand, Johannesburg, South Africa ¹⁰Department of Transfusion Medicine, Nagoya University Hospital, Nagoya, Japan ¹¹Center for Benign Haematology, Van Creveldkliniek, University Medical Center Utrecht, University Utrecht, Utrecht, Netherlands ¹²Thrombosis and Hemostasis Center, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China ¹³Novo Nordisk A/S, Søborg, Denmark ¹⁴Novo Nordisk Inc., Plainsboro, NJ, USA ¹⁵Katharine Dormandy Haemophilia and Thrombosis Centre, Royal Free Hospital, Department of Haematology, University College London, London, United Kingdom
				(409) VISUALIZATION AND CHARACTERIZATION OF VON WILLEBRAND MULTIMER BANDING PATTERNS IN ACQUIRED VON WILLEBRAND SYNDROME:A RETROSPECTIVE STUDY Serena D. Navitskas¹, Fatima Shaba², Rajiv K. Pruthi^{1, 2}, Dong Chen¹, Meera Sridharan^1,2. ¹Department of Laboratory Medicine, Rochester, MN, USA ²Department of Medicine, Rochester, MN, USA
				(410) EMICIZUMAB FOR SEVERE VON WILLEBRAND DISEASE (VWD): THE EMIVWD STUDY ENROLLMENT 2026 Jonathan C. Roberts^1,2, May Chien³, Sweta Gupta⁴, Angela Weyand⁵, Rebecca Kruse-Jarres⁶, Erin Cockrell⁷, Fernando F. Corrales-Medina⁸, Vanessa Salinas⁹, Shannon L. Carpenter¹⁰, Erin Espinoza¹¹, Abdulraheem Yacoub¹², Dayna Lenski¹, Sara Malik¹, Sarah Kreitzer¹, Michael D. Tarantino^1,2. ¹Bleeding & Clotting Disorders Institute, Dills Family Foundation Center for Research at BCDI, Peoria, IL, USA ²Departments of Pediatrics and Medicine, University of Illinois College of Medicine at Peoria, Peoria, IL, USA ³Stanford University, Stanford, CA, USA ⁴Innovative Hematology, Indiana Hemophilia and Thrombosis Center, Indianapoils, IN, USA ⁵University of Michigan Medicine, Ann Arbor, MI, USA ⁶Washington Center for Bleeding Disorders, Seattle, WA, USA ⁷St. Joseph’s Hospital Center for Bleeding and Clotting Disorders, Tampa, FL, USA ⁸Division of Pediatric Hematology-Oncology, University of Miami Miller School of Medicine, Miami, FL, USA ⁹Center for Inherited Blood Disorders, Orange, CA, USA ¹⁰Children’s Mercy, Kansas City, MO, USA ¹¹Tri-Health Cancer Institute, Cincinnati, OH, USA ¹²University of Kansas Cancer Center, Westwood Kansas, KS, USA
				(411) HEMOPHILIA LIFE STAGES AND CHANGES GLOBAL SURVEY OF PEOPLE WITH HEMOPHILIA, CAREGIVERS, AND HEMATOLOGISTS: DATA FROM UNITED STATES AND CANADIAN RESPONDENTS Mark W. Skinner^1,2, Kim Isenberg³, Pamela Wilton⁴, Andrew Wilson⁵, Lynn Malec⁶, Kyrie Smith-Jones⁵. ¹Institute for Policy Advancement, Ltd, Washington, DC, USA ²Assistant Clinical Professor, McMaster University, Hamilton, ON, Canada ³Sanofi, Minneapolis, MN, USA ⁴Canadian Hemophilia Society, Montreal, QC, Canada ⁵Sanofi, Cambridge, MA, USA ⁶Versiti Blood Research Institute Associate Professor, Division of Hematology and Oncology, Departments of Medicine and Pediatrics, Medical College of Wisconsin, Milwaukee, WI, USA
				(412) EVALUATION OF D-DIMER IN PATIENTS WITH END-STAGE RENAL DISEASE Sana Verma¹, Keerti CHAKRAVARTHY¹, Fakiha Siddiqui², Vinod Bansal², Jawed Fareed². ¹Global Thrombosis Forum, Suwanee, GA, USA ²Loyola University, Chicago, IL, USA
A7. PATHOPHYSIOLOGY OF THROMBOSIS
				(413) VENOUS THROMBOEMBOLISM OUTCOME-ONLY QUALITY MEASURES FAIL TO PROVIDE ACTIONABLE INFORMATION ABOUT PREVENTION PRACTICES Brandyn D. Lau^1,2,3,4, Michael B. Streiff^1,2, Dauryne L. Shaffer⁵, Peggy S. Kraus⁵, Elliott R. Haut^1,2,3,4. ¹Johns Hopkins School of Medicine, Baltimore, MD, USA ²Armstrong Institute for Patient Safety and Quality, Baltimore, MD, USA ³Welch Center for Prevention, Epidemiology, and Clinical Research, Baltimore, MD, USA ⁴Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA ⁵Johns Hopkins Hospital, Baltimore, MD, USA
A8. ANTITHROMBOTIC THERAPY
				(414) ONCOLOGY PROVIDER PRACTICES AND PERSPECTIVES ON AMBULATORY THROMBOPROPHYLAXIS Christina Di Carlo¹, Zayya Zendo¹, Beatrice Floris², Maria Chaudhry², Moe El-Zein², Fatima Hamad², Cristian Iannicello², Andrea Cervi^{1, 3}. ¹1Schulich School of Medicine & Dentistry, London, ON, Canada ²University of Windsor, Windsor, ON, Canada ³Department of Medical Oncology, Windsor Regional Cancer Center, Windsor, ON, Canada
				(415) MECHANISTIC POPULATION PK/PD MODELING OF FACTOR XI-TARGETING MONOCLONAL ANTIBODIES REGN7508^CAT AND REGN9933^A2 IN HEALTHY VOLUNTEERS: A FOUNDATION FOR DOSE SELECTION AND CLINICAL TRANSLATION Oleg Milberg¹, Hisham Abdallah¹, Rachel Kudgus Lokken², Robert Dingman¹, Karoline A. Meagher¹, Michael E. Burczynski¹, Ethan Marin¹, Aaron Kithcart¹, David E. Gutstein¹. ¹Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA ²Allucent, Cary, NC, USA
A9. INFORMATIONAL ABSTRACT (POSTER ONLY)
				(416) APPROPRIATENESS OF HEPARIN-INDUCED THROMBOCYTOPENIA TESTING AND ASSOCIATED PATIENT OUTCOMES ACROSS INTERMOUNTAIN HEALTH Aminah R. Altalhi, Clinton S. Anderson, Scott C. Woller, Dave S. Collingridge, Gabriel V. Fontaine. Intermountain Health, Salt Lake, UT, USA
				(417) ADDRESSING TRAVEL BARRIERS IN HEMOPHILIA CARE: FROM NEEDS ASSESSMENT TO REGIONAL SATELLITE CLINIC IMPLEMENTATION Sidney Glass, Elizabeth Hunt, Erika Martin. Virginia Commonwealth University, Richmond, VA, USA